Marker Therapeutics, Inc.

Monthly Archives: March 2017

TapImmune Announces Fully-Funded Phase 2 Breast Cancer Vaccine Study

TapImmune Inc. will likely have no profit or revenue for the foreseeable future. But the Jacksonville-based immuno-oncology company is taking steps to attract attention on Wall Street.
Read More

TapImmune to Participate in Two Upcoming Investor and Industry Conferences

Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum
Read More

Jacksonville-based TapImmune is courting investors

TapImmune Inc. will likely have no profit or revenue for the foreseeable future. But the Jacksonville-based immuno-oncology company is taking steps to attract attention on Wall Street.
Read More

US Department of Defense Funds Phase 2 Trial of TapImmune Breast Cancer Vaccine

The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $3.7 million to conduct a Phase 2 trial of TapImmune’s HER21-targeted T-cell vaccine in women with the breast cancer known as ductal carcinoma in situ (DCIS).
Read More

TapImmune Provides Year End 2016 Corporate and Clinical Update

TapImmune today provided its first quarterly business update, following the company’s uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.
Read More

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

TapImmune announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune’s HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS).
Read More

TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast

TapImmune today announced that the Company will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2016.
Read More

Doctor developing vaccine that would prevent breast, ovarian and certain lung cancers

A Jacksonville doctor is working on a vaccine that would fight off several types of cancer. He said he’s about halfway through the process before it would get to the market. A vaccine called TPIV 200 would prevent breast, ovarian and some lung cancers, and it is being created in a Mayo Clinic lab by Dr. Keith Knutson.
Read More

Jacksonville doctor developing vaccine that would prevent breast, ovarian and certain lung cancers

A Jacksonville doctor is working on a vaccine that would fight off several types of cancer. He said he’s about halfway through the process before it would get to the market. "If it works, that would be a good thing for all us women," Jacksonville resident Lakysha Tyler said.
Read More

Cancer vaccine in the works by Jacksonville doctor

A professor in Jacksonville said he’s closer to his dream of a vaccine to prevent breast, ovarian and some types of lung cancer. According to a FOX 13 report, immunology professor Dr. Keith Knutson said his dream would be to develop a vaccine to prevent cancer development.
Read More